Markets · Brief
Wegovy Cut BMI by 13.5% in Trial of Children Aged 6–11
Average BMI rose 2.7% with placebo over 68 weeks. The weekly injection is approved in the United States for obesity from age 12.

Kunkafa News · Published · 2 min read
By Kareem FaridDiscuss with the author on X
Key points
- The trial enrolled 167 children with obesity. Both groups received support with diet and physical activity.
- At week 68, 38.4% of the Wegovy group fell below the obesity threshold, compared with 2.1% on placebo.
Children aged 6 to 11 with obesity who were assigned to Wegovy saw their body mass index fall 13.5% on average over 68 weeks, while BMI rose 2.7% in the placebo group. Novo Nordisk presented the phase 3 results on Monday at ObesityWeek in Washington. The main analysis included children who stopped treatment [1].
Researchers randomly assigned 112 children to weekly semaglutide, the ingredient in Wegovy, and 55 to placebo. A separate analysis estimated that if all participants had stayed on treatment, BMI would have fallen 17.4% with Wegovy and risen 2.2% with placebo [1].
Novo reported no unexpected safety concerns and no concerns about growth or puberty during the two-year study. Whether the benefit lasts into adulthood remains unknown, Novo medical director Andrea Traina told CNBC [1] [2]. In the U.S., Wegovy injections are approved for children aged 12 and older with obesity. The label lists nausea and vomiting as common side effects. Use below age 12 remains investigational [3].
Sources: [1] Novo Nordisk, November 16 · [2] CNBC, November 16 · [3] U.S. FDA, 2026 Wegovy label.
Kunkafa forecasts
S&P 500 Index
How far it could move, which way, by when, and how confident Kunkafa is.
Check the latest forecastsMore in Markets

CalSTRS Reports $7.88bn in NVDA
Nvidia led the share positions in the September filing at $7.88bn.

Schroder Holds More IBN, Less TPR
The IBN position grew 169.4% by share count, while the TPR position fell 55.7% between June and September.

Baillie Gifford & Co Holds More LRCX, Less SPCX
The LRCX position grew 6,028,782.8% by share count, while the SPCX position fell 24.1% between June and September.